What are the other details besides the two year term of the
What are the other details besides the two year term of the loan. After all 21mil net in two years is a big challenge. No BB for the next two years maybe even more I would think. I always thought the funding partners are investors to the fund. That is what I understood when this all started. The fund manager decides where to invest and no input from the investors (funding partners). But I could be wrong.
I for one been averaging since .17 cents. Safe to say, been wrong all that time. So I set some forms/events to occur before I resume to buy again. Oh, I stop buying at .05. Have no buys below that up to the present. I continue to watch and will jump in when I see the events I am waiting. Don’t mind chasing if that is the case. GLA
GO NTEK
3
Nanotech Entertainment Inc. (NTEK) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Four Ways to Experience Urban Leisure in Panama Marriott International has put together four exciting suggestions for enjoying a lively vacation in Panama's urban environment. This dynamic city is an ideal spot for urban leisure, offering easy access by air, a mix of historical landmarks, and contemporary architecture. Discovering Panamá Viejo and Casco Viejo Begin your...
Continue Reading
Analyzing P/E Ratios: What Investors Should Know In the ever-evolving landscape of the stock market, PTC Inc. has captured attention with its recent price of $170.90, reflecting a modest increase of 1.77%. Despite this recent uptick, the company has experienced a downturn of 8.94% over the past month and a 3.27% decline over the past year. This fluctuation raises an...
Continue Reading
Understanding the Multicore Processors Market Expansion As the digital age continues to thrive, the multicore processors market is also witnessing an impressive trajectory, thanks to the growing need for advanced computing solutions across various industries. Multicore processors, which allow for simultaneous processing on multiple cores, are essential for delivering...
Continue Reading
Switch Therapeutics' New Direction with Dr. David M. Holtzman Switch Therapeutics, a pioneering biotechnology firm focused on developing advanced RNA therapeutics for central nervous system diseases, has recently announced an exciting new chapter in its growth. The company has appointed Dr. David M. Holtzman, a leading expert in neurology, to its Scientific Advisory...
Continue Reading
Market Overview and Key Stock Movements This morning, U.S. stock futures looked to open higher, with the Dow futures up by approximately 0.1%. However, some major stocks faced notable declines in pre-market trading sessions, prompting attention from investors. Inspire Medical Systems Faces Setback Inspire Medical Systems, Inc. experienced a significant drop in pre-market...
Continue Reading
